Herpes simplex virus type 2 (HSV-2) is a common pathogen coinfecting more than half of human immunodeficiency virus (HIV)-infected adults [1] , and has been postulated to accelerate HIV disease progression based on cross-sectional and short-term studies linking it to increased plasma HIV load [2, 3] . However, few studies have quantified the relationship between HSV-2 seropositivity and longitudinal measures of HIV disease progression. Such information would be useful in several ways. First, it could inform the counseling of patients regarding HIV prognosis [4] . Second, because clinical trials among HIV/HSV-2-coinfected adults have associated acyclovir 400 mg twice daily with modest attenuations in HIV disease progression [5, 6] , it could aid in identifying the maximum potential benefits of HSV-2 suppressive therapy; acyclovir dosing should ostensibly be escalated until the full magnitude of HSV-2-associated harms is reversed. Furthermore, given recent in vitro data showing that acyclovir has direct anti-HIV activity [7, 8] , comparing the magnitude of clinical benefit associated with acyclovir with the potential magnitude of harm associated with HSV-2 coinfection could help determine whether acyclovir exerts clinically relevant anti-HIV activity in vivo.
The primary objective of this retrospective cohort study was thus to compare the annual rate of CD4 count decline in adults not using highly active antiretroviral therapy (HAART), according to HSV-2 serostatus. The secondary objective was to evaluate the time to HAART initiation or reaching a CD4 count ≤50 cells/mm 3 according to HSV-2 serostatus. The impact of HSV-1 coinfection was also considered because of its potential relevance for understanding HIV disease progression [9] .
METHODS

Participants
HIV-infected adults were recruited prospectively between January 2009 and August 2011 from 6 primary care and hospital clinic sites in Toronto, Canada. In addition, participants recruited between January 2006 and June 2009 into a separate HIV/HSV-2 coinfection study among women at a hospitalbased HIV clinic in Hamilton, Canada, were also included if they met eligibility criteria. Eligibility criteria included documented HIV infection and baseline age at least 18 years; participants also needed to have a previous period of follow-up of at least 3 months during which there were at least 3 consecutive CD4 count measurements (the first between 400 and 900 cells/mm 3 ), no exposure to antiretroviral therapy (ART), no receipt of chronic suppressive anti-HSV therapy (≥1 month's use of acyclovir, valacyclovir, and/or famciclovir), and no exposure to immunomodulatory drugs. Individuals were excluded if they fit the phenotype of an HIV long-term nonprogressor (defined here as HIV infection ≥5 years, CD4 count consistently ≥500 cells/mm 3 , and plasma HIV load < 1000 copies/mL without ART based on criteria adapted from other studies) [10] [11] [12] .
Determination of HSV Serostatus
For Toronto participants, HSV-1 and HSV-2 serostatus was ascertained for the period of follow-up by accessing stored plasma specimens from the Ontario Public Health Laboratory (PHL). The Ontario PHL performs all HIV load testing in Ontario and routinely stores leftover plasma when feasible. Baseline type-specific HSV serostatus was assessed using the sample closest in date to that of the first eligible CD4 count measurement and the HerpeSelect glycoprotein G-1 (gG-1) and gG-2 enzyme-linked immunosorbent assay (ELISA; Focus Technologies, Cypress, California). Primary analyses employed the manufacturer's recommended threshold value of 1.1 for defining HSV-2 seropositivity. For individuals initially testing HSV-2 seronegative, a subsequent sample closest in date to the end of their follow-up period was tested to assess for seroconversion. The end of the follow-up period, or primary endpoint, was defined as the date of HAART initiation, or the first of 2 consecutive dates with CD4 ≤350 cells/mm 3 . Indeterminate results were retested, and repeated indeterminate results were excluded. For Hamilton participants, HSV type-specific serostatus was ascertained only at the time of enrollment into the parent study using the same assay.
Clinical Data
Participants completed a brief questionnaire regarding herpes symptoms and treatment. Additional demographic, clinical, and laboratory data were obtained via medical records review and electronic extraction from clinic databases.
Sample Size Considerations
Using formulae that account for repeated measures [13] , a base sample size of 250 participants (125 per group) was estimated to be able to detect an increase of at least 10 cells/mm 3 in the annual rate of CD4 decline associated with HSV-2 infection with 80% power and 2-sided α = .05, assuming 11 visits per patient, 2.5 years of follow-up, baseline CD4 standard deviation = 135 cells/mm 3 , and a correlation coefficient of 0.65 for intraindividual CD4 counts. This estimate was adjusted to a final target sample size of 288 to account both for anticipated HSV-2 seroconversions based on published seroincidence rates [14] , and for slightly unequal group sizes, based on 54.4% HSV-2 seroprevalence among Canadian HIV patients [1] .
A difference in the annual rate of CD4 count decline of 10 cells/mm 3 represents a 20% increase over the average rate of decline at this stage of disease [15, 16] , and hence was considered clinically meaningful, particularly when considering accumulated impact over multiple years.
Data Analysis
The primary analysis was a random effects regression model [13] , with the dependent variable equal to participants' CD4 count. The primary covariate of interest was the interaction between HSV-2 status and time from baseline. After inclusion of participant sex, additional variables were considered for inclusion in multivariable models if they produced changes of ≥10% in the parameter estimate for the primary predictor; after further elimination of candidate variables due to collinearity or small cell sizes, the final model was selected based on model fit. Because HSV-2 is postulated to accelerate HIV disease progression by increasing HIV load, the viral load setpoint (defined here as the mean of the first 3 log 10 -transformed measurements) was included only in exploratory analyses. As a secondary analysis, a proportional hazards survival model was constructed in which the primary outcome was the time from baseline until either 2 consecutive CD4 counts ≤350 cells/mm 3 , or actual initiation of HAART for any reason. Participants meeting neither criterion were right-censored at the time of their last follow-up CD4 count.
Sensitivity analyses were conducted using the CD4 percentage instead of the absolute CD4 count in random effects models, using only the first 2 or 3 years of follow-up data, and after excluding patients from the Hamilton site, where HSV serostatus was ascertained at the time of enrollment and thus could not rule out HSV-2 seroconversion during follow-up. Finally, because some studies have recommended a higher laboratory threshold for defining HSV-2 seropositivity among HIV patients using the HerpeSelect 2 ELISA [17] [18] [19] , sensitivity analyses were also conducted using a cutoff of 3.5; results in the 0.9-3.5 range were considered equivocal and excluded from this analysis. All statistical analyses were conducted using SAS software, version 9.3.
Ethical Approval
Local research ethics board approval was obtained for each site prior to commencing study activities. Individual participants provided written informed consent.
RESULTS
Participant Characteristics
330 participants were recruited, of whom 112 were excluded because they were HSV-2 seroconverters (n = 21 participants), had inadequate CD4 follow-up data (n = 21), never had a baseline CD4 count in the eligible range (n = 20), did not have archived plasma available for HSV serology testing at baseline (n = 14) or follow-up (n = 6), had equivocal HSV-2 serology results (n = 10), were enrolled in error (n = 7 on HAART, n = 5 long-term nonprogressors, n = 4 repeat enrollments, n = 3 on disallowed medications), or withdrew consent (n = 1). Charac- teristics of the 218 included individuals are shown in Table 1 . The HSV-2 seropositive group included more women, black and heterosexual individuals, and immigrants from HIVendemic countries. They were also more likely to report prior genital but not oral or anal herpes symptoms. 
Herpes Characteristics
Self-reported clinical characteristics and laboratory-determined serologic status for herpes are provided in Table 2 . Roughly half (106/218 or 48.6%) of participants reported any history of herpes symptoms, most commonly oral herpes. Among those reporting any symptoms, most reported 1 or fewer outbreaks per year. Time since the first herpes outbreak was often not reported, but available responses generally suggested a long duration of infection. Correlations between symptom histories and type-specific serostatus were weak, consistent with previous findings that symptom history is a poor proxy for HSV serostatus [20] .
Random Effects Models
Relationships with CD4 count over time are shown both for individual participant characteristics, and for the interaction of participant characteristics with time, in Table 3 . The former terms (column A) represent associations with overall CD4 counts, whereas the latter terms (column B) represent associations with annual rates of change in CD4 count and were the parameters of greater interest in this study. Each year of followup was associated with a statistically significant decrease in CD4 count of roughly 50 cells/mm 3 . Each log 10 increase in HIV load, female sex, and black race was also each associated with significantly lower overall CD4 counts, whereas a history of oral herpes was associated with higher CD4 counts.
Each log 10 increase in HIV load was further associated with a statistically significant acceleration in the rate of CD4 count decline of roughly 25 cells/mm 3 /year. Coinfection with hepatitis C was also associated with more rapid CD4 count decline, by approximately 45 cells/mm 3 /year. In contrast, black race, having a country of birth other than Canada, and, in particular, immigration to Canada within the preceding 10 years were each associated with more favorable rates of CD4 count decline by roughly 30 cells/mm 3 /year. No association was observed between HSV-2 status ( Figure 1A ), HSV-1 status, or self-reported herpes symptoms with the speed of HIV disease progression. Results were qualitatively unchanged when herpes symptoms were excluded from the model. In the multivariable random effects model (Table 3 , column C), after adjustment for sex, HSV-1 serostatus, oral and genital herpes symptoms, immigrant status, and the interaction of immigrant status with time, no statistically significant relationship was observed between HSV-2 serostatus and the rate of CD4 count decline. As in the univariate models, recent immigrant status was associated with an attenuated rate of CD4 count decline. HSV-1 status and self-reported HSV symptoms were not associated with CD4 count. Exploratory models incorporating HIV load setpoint showed a strong independent relationship with lower CD4 counts at roughly −70 cells/mm 3 per log 10 increase (P < .0001), but did not qualitatively change the conclusions (data not shown). Qualitative conclusions were also unchanged in sensitivity analyses using CD4 percentage instead of absolute CD4 count, using only the first 2 or 3 years of follow-up data, using only participants in whom HSV-2 status was ascertained based on archived specimens, and using a cutoff of 3.5 to define HSV-2 seropositivity. 
Analysis of Time to Composite Endpoint
In the proportional hazards model (Table 4) In contrast to the results of the mixed model, however, HSV-2 infection was associated with a significantly increased rate of disease progression (HR = 2.08; 95% CI, 1.36-3.17), as was female sex (HR = 1.93; 95% CI, 1.31-2.84) in these models ( Figure 1B ). Both these relationships persisted in multivariable analysis including baseline CD4 count and a history of genital herpes symptoms, with adjusted HR = 2.07 for HSV-2 (95% CI, 1.28-3.33) and 2.00 for female sex (95% CI, 1.30-3.08). These conclusions were unchanged in sensitivity analyses using only participants in whom HSV-2 status was ascertained based on archived specimens, and using the higher laboratory cutoff of 3.5 for defining HSV-2 seropositivity. Incident pregnancy did not explain the increased HAART initiation in women; of the 15 women meeting the primary composite endpoint based on initiating HAART, chart review revealed that only 2 were definitely pregnant, 10 were definitely not pregnant, and a determination could not be made in 3. Excluding the 5 with known or uncertain pregnancy status did not qualitatively change the results.
DISCUSSION
Although HSV-2 coinfection has been hypothesized to adversely affect HIV disease progression, we observed no difference in the rate of CD4 count decline among HSV-2 seropositive versus seronegative antiretroviral-naive HIV-infected adults. Furthermore, no impact of self-reported HSV symptoms nor of HSV-1 was evident, and sensitivity analyses using CD4 percentages and incorporating more stringent laboratory criteria for defining HSV-2 seropositivity (HerpeSelect ELISA cutoff of 3.5) further failed to observe a difference. As we have summarized in a recent systematic review [21] , these results are consistent with those of previous studies generally showing no conclusive relationship between HSV-2 seropositivity and HIV disease progression [22] [23] [24] .
How might these findings be reconciled with prior molecular, clinical, and epidemiologic data linking HSV-2 to increased plasma HIV load? One explanation may be that HSV-2 serostatus fails to take into account the duration of HSV-2 infection and level of HSV-2 activity. Because the natural history of HSV-2 is characterized by a decreasing frequency of reactivations over time [25, 26] , overrepresentation of individuals with longstanding infection may produce HSV-2 seropositive cohorts with relatively inactive HSV-2. Although asymptomatic HSV-2 infection may still result in frequent viral shedding [27] , the short duration and low HSV copy number associated with these events may be insufficient to drive clinically relevant increases in HIV load. Alternatively, modest HSV-2-related elevations in HIV load may be insufficient to drive appreciable differences in CD4 count decline.
Whether an appreciable adverse impact of HSV-2 on HIV exists among subgroups, such as those with recently acquired and/or more clinically active herpes, remains to be determined. Although 21 patients acquired HSV-2 infection during the follow-up period, their relatively low numbers and logistical/ financial constraints precluded an evaluation of the impact of incident HSV-2 on HIV disease progression. Previous studies involving recent HSV-2 seroconverters have been unable to demonstrate any effect on plasma HIV load or CD4 count [28, 29] , but have been limited by small sample sizes.
Because preexisting HSV-1 infection may attenuate the clinical severity of subsequently acquired HSV-2 [30, 31] , the high prevalence of HSV-1 among HSV-2 seropositive participants (72.4%) in this study could also have contributed to the null result. However, the sequence in which participants with both HSV types acquired their infections is not definitively known. Our findings must be reconciled with recent clinical trials showing attenuated HIV disease progression and lower plasma HIV load with acyclovir in coinfected individuals [5, 6] . Such effects would not be predicted from the results of this study if suppression of HSV-2-driven HIV replication were the sole mechanism underlying these benefits. One explanation is that antiherpetic medications may have direct anti-HIV activity as demonstrated in vitro [7, 8] , and/or that suppression of HSV-2 attenuates inflammatory responses that contribute to HIV disease progression; further mechanistic research in this area is needed.
Interestingly, despite the lack of association with CD4 count decline, we also found that HSV-2 seropositivity was associated with accelerated disease progression in time-toevent analysis, using the composite outcome of HAART initiation or CD4 <350 cells/mm 3 . Because reasons for HAART initiation were not available, and because HAART is often initiated because of HIV disease progression, it was challenging to disaggregate the components of this composite outcome. It is plausible that this finding was driven by earlier HAART initiation in the coinfected group. Previous studies of coinfected adults have observed modestly shortened times to opportunistic infection but not to CD4 count thresholds, potentially because community-acquired pneumonia, zoster, tuberculosis, or other conditions can occur regardless of CD4 count, in turn prompting HAART initiation [24, 32] . Alternatively, HSV-2 seropositive patients and providers may have desired earlier HAART initiation based on knowledge about HSV-2 status, or the relationship between HSV-2 and HAART may be confounded by an unmeasured variable such as high-risk sexual activity. Recent immigrant status was the only characteristic associated with the rate of CD4 count decline, conferring a protective effect of approximately 30 cells/mm 3 /year. This finding is consistent with prior work observing lower mortality among recent immigrants to Canada [33] , and may have resulted from an overrepresentation of HIV subtypes known to portend a more favorable prognosis among recent immigrants (eg, clades A and C) [34] ; clade data were not available.
Strengths of this study include its broad eligibility criteria, careful ascertainment of HSV-2 serostatus during the follow-up period with exclusion of HSV-2 seroconverters, and exclusion of long-term nonprogressors and important confounders such as antiretroviral and antiherpetic medication use. The observed rate of CD4 count decline overall and association with HIV load are consistent with results from other published literature on large cohorts of adults with untreated HIV infection [16, 35] .
This study has limitations that warrant consideration. First, lack of available archived plasma produced shorter than expected periods of follow-up time or exclusion from the study altogether for 96 and 20 participants, respectively. These challenges may have reduced statistical power, although the magnitude of any such effect is likely small. Second, despite careful chart review to exclude patients using chronic suppressive anti-HSV therapy, undocumented medication use could have biased toward the null. Third, although we attempted to exclude long-term nonprogressors using criteria adapted from other studies [10] [11] [12] , some such individuals may nevertheless have been included, and our requirement for baseline CD4 counts of 400-900 cells/mm 3 may have selected patients with relatively stable disease. Fourth, CD4 counts were not all performed in the same laboratories. However, individual patients generally performed testing in the same facilities, such that patients' rates of CD4 count decline were unlikely affected by this source of variability. Finally, enrolling participants from clinical cohorts of actively followed HIV patients may have introduced prevalence-incidence or Neyman bias [36, 37] , which can bias a study in either direction as historically followed patients (with either unusually favorable or unfavorable prognosis) could not be approached regarding study participation. However, this bias is a limitation of our retrospective cohort design, and this enrollment strategy was required to obtain informed consent for testing of archived plasma. In summary, we found that HSV-2 seropositivity had no significant impact on the rate of CD4 count decline in HAARTuntreated HIV, but was associated with an earlier combined endpoint of ART initiation or CD4 count <350 cells/mm 3 . Further work is needed to better define the potential roles of anti-HSV medications in HIV infection.
Notes
